ECSP22022403A - Proceso industrial para la preparación de estetrol de alta pureza - Google Patents
Proceso industrial para la preparación de estetrol de alta purezaInfo
- Publication number
- ECSP22022403A ECSP22022403A ECSENADI202222403A ECDI202222403A ECSP22022403A EC SP22022403 A ECSP22022403 A EC SP22022403A EC SENADI202222403 A ECSENADI202222403 A EC SENADI202222403A EC DI202222403 A ECDI202222403 A EC DI202222403A EC SP22022403 A ECSP22022403 A EC SP22022403A
- Authority
- EC
- Ecuador
- Prior art keywords
- estetrol
- preparation
- high purity
- industrial process
- formula
- Prior art date
Links
- AJIPIJNNOJSSQC-NYLIRDPKSA-N estetrol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)[C@@H]4O)O)[C@@H]4[C@@H]3CCC2=C1 AJIPIJNNOJSSQC-NYLIRDPKSA-N 0.000 title abstract 3
- 229950009589 estetrol Drugs 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 239000013067 intermediate product Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a la preparación de estetrol de fórmula (I), derivados del mismo protegido en las posiciones 3,15α,16α,17β de fórmula general (III), y derivados 3-hidroxi del mismo protegido en las posiciones 15α,16α,17β de fórmula general (IV), y a los productos intermedios de fórmulas generales (III) y (IV) aplicados en el proceso. Otro aspecto de la invención es la aplicación de estetrol de fórmula (I) obtenido por el proceso de la invención para la preparación de una composición farmacéutica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1900315A HU231240B1 (hu) | 2019-09-03 | 2019-09-03 | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
PCT/IB2020/058148 WO2021044302A1 (en) | 2019-09-03 | 2020-09-02 | Industrial process for the preparation of high purity estetrol |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP22022403A true ECSP22022403A (es) | 2022-04-29 |
Family
ID=89992977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202222403A ECSP22022403A (es) | 2019-09-03 | 2022-03-24 | Proceso industrial para la preparación de estetrol de alta pureza |
Country Status (29)
Country | Link |
---|---|
US (1) | US11633406B2 (es) |
EP (1) | EP3877395B1 (es) |
JP (1) | JP7265087B2 (es) |
KR (1) | KR20220071206A (es) |
CN (1) | CN114302889B (es) |
AU (1) | AU2020343497B2 (es) |
CA (1) | CA3147815C (es) |
CL (1) | CL2022000492A1 (es) |
CO (1) | CO2022003769A2 (es) |
CU (1) | CU24692B1 (es) |
DK (1) | DK3877395T3 (es) |
EC (1) | ECSP22022403A (es) |
ES (1) | ES2855923T3 (es) |
FI (1) | FI3877395T3 (es) |
HR (1) | HRP20230230T1 (es) |
HU (2) | HU231240B1 (es) |
IL (1) | IL290973B2 (es) |
JO (1) | JOP20220041A1 (es) |
LT (1) | LT3877395T (es) |
MA (1) | MA54200B1 (es) |
MD (1) | MD3877395T2 (es) |
MX (1) | MX2022002603A (es) |
PE (1) | PE20221418A1 (es) |
PL (1) | PL3877395T3 (es) |
PT (1) | PT3877395T (es) |
RS (1) | RS63966B1 (es) |
SI (1) | SI3877395T1 (es) |
WO (1) | WO2021044302A1 (es) |
ZA (1) | ZA202203557B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3151465C (en) * | 2019-09-27 | 2024-05-07 | Roberto Lenna | Process for preparing (15a,16a,17b)-estra-1,3,5(10)-triene-3,15,16,17-tetrol (estetrol) and intermediates of said process |
AU2021467221A1 (en) * | 2021-10-01 | 2024-05-16 | Industriale Chimica S.R.L. | Process for preparing (15alpha,16alpha,17 eta)-estra-1,3,5(10)-triene-3,15,16,17-tetrol (estetrol) monohydrate |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
DK1390040T3 (da) | 2001-05-18 | 2007-04-23 | Pantarhei Bioscience Bv | Farmaceutisk præparat til anvendelse i hormonerstatningsterapi |
US7871995B2 (en) | 2001-05-23 | 2011-01-18 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
WO2002094279A1 (en) | 2001-05-23 | 2002-11-28 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahidroxilated estrogen for use in hormonal contraception |
ES2278925T3 (es) | 2001-11-15 | 2007-08-16 | Pantarhei Bioscience B.V. | Uso de compuestos estrogenicos en combinacion con compuestos progestogenicos en terapias de sustitucion hormonal. |
AU2003274941A1 (en) | 2002-06-11 | 2003-12-22 | Pantarhei Bioscience B.V. | A method of treating human skin and a skin care composition for use in such a method |
ATE340579T1 (de) | 2002-06-11 | 2006-10-15 | Pantarhei Bioscience Bv | Methode zur behandlung oder prävention immunologischer erkrankungen und pharmazeutische zusammensetzung zur solchen anwendung |
AU2003253506A1 (en) | 2002-07-12 | 2004-02-02 | Pantarhei Biosciences B.V. | Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy |
PT1556058E (pt) | 2002-10-23 | 2008-03-20 | Pantarhei Bioscience Bv | Composições farmacêuticas que compreendem derivados do estretol para serem utilizadas no tratamento do cancro |
DK1562976T3 (da) | 2002-11-08 | 2010-08-16 | Pantarhei Bioscience Bv | Syntese af estetrol via estron-afledte steroider |
US20090221540A1 (en) | 2006-01-09 | 2009-09-03 | Pantarhei Bioscience B.V. | Method of Treating An Acute Vascular Disorder |
WO2008085038A2 (en) | 2007-01-08 | 2008-07-17 | Pantarhei Bioscience B.V. | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
DK2741824T3 (en) | 2011-08-11 | 2017-07-10 | Estetra Sprl | Use of estetrol as emergency contraception |
EA024003B1 (ru) | 2011-10-07 | 2016-08-31 | Эстетра С.П.Р.Л. | Способ получения эстетрола |
EP2653163A1 (en) | 2012-04-19 | 2013-10-23 | Université de Liège | Estrogenic components for use in the treatment of neurological disorders |
WO2013034780A2 (en) | 2012-12-20 | 2013-03-14 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol and related compounds |
CA2924255C (en) | 2013-09-18 | 2022-11-22 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol |
SI3079671T1 (en) | 2013-12-12 | 2018-04-30 | Donesta Bioscience B.V. | Oral disintegration solid dosage form containing an esterol component |
MD3310345T2 (ro) | 2015-06-18 | 2021-07-31 | Estetra Sprl | Comprimată orodispersabilă ce conține estetrol |
EP3701944B1 (en) | 2015-06-18 | 2021-12-08 | Estetra SRL | Orodispersible dosage unit containing an estetrol component |
MD3310346T2 (ro) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Comprimată orodispersabilă ce conține estetrol |
CA3041016C (en) | 2016-10-28 | 2023-09-05 | Estetra Sprl | Method for the management of dysmenorrhea and menstrual pain |
CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
EP3661520B1 (en) | 2017-08-01 | 2021-12-01 | Fund SA | Adjuvant therapy for use in prostate cancer treatment |
JOP20200169A1 (ar) | 2018-02-07 | 2020-07-07 | Estetra Sprl | تركيبة لمنع الحمل بتأثيرات منخفضة على القلب والأوعية |
CA3151465C (en) * | 2019-09-27 | 2024-05-07 | Roberto Lenna | Process for preparing (15a,16a,17b)-estra-1,3,5(10)-triene-3,15,16,17-tetrol (estetrol) and intermediates of said process |
-
2019
- 2019-09-03 HU HU1900315A patent/HU231240B1/hu unknown
-
2020
- 2020-09-02 MA MA54200A patent/MA54200B1/fr unknown
- 2020-09-02 ES ES20768398T patent/ES2855923T3/es active Active
- 2020-09-02 RS RS20230112A patent/RS63966B1/sr unknown
- 2020-09-02 HR HRP20230230TT patent/HRP20230230T1/hr unknown
- 2020-09-02 PL PL20768398.8T patent/PL3877395T3/pl unknown
- 2020-09-02 SI SI202030156T patent/SI3877395T1/sl unknown
- 2020-09-02 PT PT207683988T patent/PT3877395T/pt unknown
- 2020-09-02 WO PCT/IB2020/058148 patent/WO2021044302A1/en active Application Filing
- 2020-09-02 CN CN202080061521.1A patent/CN114302889B/zh active Active
- 2020-09-02 PE PE2022000348A patent/PE20221418A1/es unknown
- 2020-09-02 KR KR1020227010919A patent/KR20220071206A/ko unknown
- 2020-09-02 AU AU2020343497A patent/AU2020343497B2/en active Active
- 2020-09-02 HU HUE20768398A patent/HUE061427T2/hu unknown
- 2020-09-02 DK DK20768398.8T patent/DK3877395T3/da active
- 2020-09-02 MX MX2022002603A patent/MX2022002603A/es unknown
- 2020-09-02 FI FIEP20768398.8T patent/FI3877395T3/fi active
- 2020-09-02 LT LTEPPCT/IB2020/058148T patent/LT3877395T/lt unknown
- 2020-09-02 CU CU2022000013A patent/CU24692B1/es unknown
- 2020-09-02 US US17/639,206 patent/US11633406B2/en active Active
- 2020-09-02 IL IL290973A patent/IL290973B2/en unknown
- 2020-09-02 EP EP20768398.8A patent/EP3877395B1/en active Active
- 2020-09-02 JO JOP/2022/0041A patent/JOP20220041A1/ar unknown
- 2020-09-02 MD MDE20210894T patent/MD3877395T2/ro unknown
- 2020-09-02 CA CA3147815A patent/CA3147815C/en active Active
- 2020-09-02 JP JP2022511285A patent/JP7265087B2/ja active Active
-
2022
- 2022-02-28 CL CL2022000492A patent/CL2022000492A1/es unknown
- 2022-03-24 EC ECSENADI202222403A patent/ECSP22022403A/es unknown
- 2022-03-28 ZA ZA2022/03557A patent/ZA202203557B/en unknown
- 2022-03-29 CO CONC2022/0003769A patent/CO2022003769A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP22022403A (es) | Proceso industrial para la preparación de estetrol de alta pureza | |
CL2020002695A1 (es) | Péptidos macrocíclicos contra actinetobacter baumannii | |
BR112015012425A2 (pt) | composto, composição farmacêutica, método e medicamento para o tratamento de doenças medicadas pela proteína parp-1 e uso do composto | |
CR20150313A (es) | Composiciones farmacéuticas | |
CR20180232A (es) | Macrociclos peptídicos contra acinetobacter baumannii | |
AR094876A1 (es) | Derivados de ácido betulínico modificados con alquilo c-3 y alquenilo | |
BR112017023764A2 (pt) | derivados de ciclohexano substituído por amido | |
BR112018075433A2 (pt) | derivados de piperidinila, processo para sua preparação e composições farmacêuticas contendo-os | |
UY31631A1 (es) | Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones | |
PA8547701A1 (es) | Nucleosidos 4 substituidos. | |
CO6670589A2 (es) | Compuestos para reducir la producción de beta-amiloide | |
CO6270324A2 (es) | Derivados de pirimidina para el tratamiento del asma epoc rinitis conjutivitis alergica dermatitis atopica cancer hepatitis b hepatitis c vih vph infecciones bacterianas y dermatosis | |
UY31046A1 (es) | Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones | |
CR20190504A (es) | COMPUESTO DE AMIDA (Divisional 2015-0454) | |
CO2020011852A2 (es) | Inhibidores de canales receptores de potencial transitorio de oxadiazol | |
UY32240A (es) | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. | |
CL2019003281A1 (es) | Derivados de piperidina. (divisional solicitud 201900169) | |
MX2020004785A (es) | Proceso para preparar tapinarof. | |
AR126168A2 (es) | Producto farmacológico que comprende colagenasa | |
CL2018002095A1 (es) | Un derivado de piridina representado por las formulas i a iii y una sal farmacéuticamente aceptable del mismo; procedimiento de preparación del derivado de piridina o la sal farmacéuticamente aceptable del mismo; composición farmacéutica y su uso para preparar un medicamento útil para la prevención o tratamiento de una enfermedad de crecimiento celular anómalo producida por una mutación ras. | |
CL2022003646A1 (es) | Derivados de amidopirimidona | |
CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
BR112022013322A2 (pt) | Derivado de tetra-hidroisoquinolina tricíclico, método de preparação para o mesmo e aplicação do mesmo em medicina | |
BR112022000914A2 (pt) | Composição farmacêutica |